Havrix 720 Kinder

Havrix 720 Kinder is a hepatitis A vaccine containing inactivated hepatitis A virus and algeldrate as an adjuvant, supplied as an injectable solution for intramuscular use. The product is marketed in the European Union and is prescribed by health professionals for active immunisation against hepatitis A infection. It is a prescription‑only vaccine that stimulates the body’s immune response to provide protective antibodies in children and adolescents.

Havrix 720 Kinder is indicated for the prevention of hepatitis A infection in individuals for whom active immunisation is appropriate.

- Primary prophylaxis for hepatitis A in children and adolescents. - Boosting immunity in persons previously vaccinated with another hepatitis A vaccine. - Use in travelers to regions with intermediate or high hepatitis A endemicity. - Administration as part of routine childhood immunisation schedules where recommended. - Protection of individuals with chronic liver disease who are at increased risk of severe hepatitis A. - May be co‑administered with other routine childhood vaccines according to local immunisation guidelines.

Following intramuscular injection, Havrix 720 Kinder can cause a range of adverse reactions, most of which are mild and resolve without medical intervention.

Common: - Pain, redness or swelling at the injection site. - Low‑grade fever lasting 24–48 hours. - Headache or mild fatigue. - Transient nausea or abdominal discomfort. - Mild muscle aches or joint pain. - Temporary dizziness or feeling of weakness. - Slight swelling of lymph nodes near the injection area.

Serious: - Severe allergic reaction (anaphylaxis) with difficulty breathing, hives or swelling of the face. - Neurological events such as Guillain‑Barré syndrome, although rare. - Persistent high fever (>39 °C) lasting more than 48 hours. - Onset of rash or urticaria beyond the injection site.

Healthcare providers should evaluate individual health status before administering Havrix 720 Kinder and observe recommended safety measures.

- Confirm no history of severe allergic reaction to any component of the vaccine. - Defer vaccination in persons with acute moderate or severe illness until recovery. - Assess for immunocompromised conditions; vaccine may be less effective in such individuals. - Consider postponement in pregnant women unless benefits outweigh potential risks. - Review current medications that may affect immune response, such as immunosuppressants. - Ensure proper intramuscular injection technique to minimize local reactions. - Document lot number and administration date for pharmacovigilance.

Havrix 720 Kinder may interact with other agents that influence immune function or increase the risk of hypersensitivity.

Avoid: - Concurrent administration with live viral vaccines (e.g., measles, mumps, rubella) should be avoided within 4 weeks. - Use with other inactivated hepatitis A vaccines or duplicate dosing.

Use with caution: - Immunosuppressive therapy (e.g., corticosteroids, biologics) may reduce vaccine efficacy; monitor antibody response. - Antipyretics such as acetaminophen or ibuprofen can be given to manage post‑vaccination fever, but routine prophylactic use may blunt antibody production. - Blood products or immunoglobulins given within 2 weeks before or after vaccination may interfere with immune response. - Allergy testing agents containing gelatin or other excipients should be considered if the patient has known sensitivities.